Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy DRMA?
Source: Newsfilter
XYNGARI™ Phase 3 Trial Update: Dermata Therapeutics has completed patient visits for its pivotal Phase 3 STAR-1 trial of XYNGARI™, a novel topical treatment for moderate-to-severe acne, with topline results expected by the end of March 2025.
Acne Treatment Market Need: Over 30 million patients in the U.S. seek acne treatment annually, highlighting a significant unmet need for effective therapies like XYNGARI™, which aims to provide a convenient and well-tolerated alternative to traditional treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRMA
Wall Street analysts forecast DRMA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.350
Low
10.00
Averages
10.00
High
10.00
Current: 1.350
Low
10.00
Averages
10.00
High
10.00
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
TEN Holdings Inc. Announces $2.25 Million Private Placement, Shares Surge 16.31%
- Private Placement: TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 16.31% surge in stock price, indicating strong market confidence in its financing strategy.
- Market Performance: Despite a weaker price trend in the short term, this financing could provide essential capital support, enhancing the company's operational capabilities and competitive edge in the market.
- Industry Impact: The financing initiative by TEN Holdings is particularly significant in the current economic climate, especially as investor interest in emerging markets rises, potentially attracting more attention from investors.
- Strategic Outlook: Through this private placement, TEN Holdings not only improves its capital structure but also lays the groundwork for future expansion and innovation, thereby enhancing its position within the industry.
See More
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Dermata Therapeutics (DRMA) Raises $4.1M by Issuing 2.02M Shares at $2.04 Each
- Financing Scale: Dermata Therapeutics announced the issuance of 2.02 million shares of common stock and Series C and D warrants at $2.04 each, generating $4.1 million upfront and the potential for an additional $8.3 million if all warrants are exercised, enhancing the company's liquidity for future growth.
- Use of Proceeds: The funds raised will be allocated for consumer research studies, pre-launch activities for a new over-the-counter acne kit, acquisitions of synergistic companies, and development of emerging technologies, aimed at improving product competitiveness and accelerating company growth.
- Insider Participation: Dermata's executives, including the CEO and CFO, are participating on the same terms as other investors, demonstrating management's confidence in the company's future and potentially increasing investor trust in the firm.
- Market Performance: Over the past year, DRMA's stock price fluctuated between $1.96 and $23.7, closing 16.18% higher at $2.37 on Wednesday, reflecting a positive market reaction to the financing and the company's outlook.
See More
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
See More
TEN Holdings Inc. Announces $2.25 Million Private Placement, Shares Surge 16.31%
- Private Placement: TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 16.31% surge in stock price, indicating strong market confidence in its financing strategy.
- Market Performance: Despite a weaker price trend in the short term, this financing could provide essential capital support, enhancing the company's operational capabilities and competitive edge in the market.
- Industry Impact: The financing initiative by TEN Holdings is particularly significant in the current economic climate, especially as investor interest in emerging markets rises, potentially attracting more attention from investors.
- Strategic Outlook: Through this private placement, TEN Holdings not only improves its capital structure but also lays the groundwork for future expansion and innovation, thereby enhancing its position within the industry.
See More
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Dermata Therapeutics (DRMA) Raises $4.1M by Issuing 2.02M Shares at $2.04 Each
- Financing Scale: Dermata Therapeutics announced the issuance of 2.02 million shares of common stock and Series C and D warrants at $2.04 each, generating $4.1 million upfront and the potential for an additional $8.3 million if all warrants are exercised, enhancing the company's liquidity for future growth.
- Use of Proceeds: The funds raised will be allocated for consumer research studies, pre-launch activities for a new over-the-counter acne kit, acquisitions of synergistic companies, and development of emerging technologies, aimed at improving product competitiveness and accelerating company growth.
- Insider Participation: Dermata's executives, including the CEO and CFO, are participating on the same terms as other investors, demonstrating management's confidence in the company's future and potentially increasing investor trust in the firm.
- Market Performance: Over the past year, DRMA's stock price fluctuated between $1.96 and $23.7, closing 16.18% higher at $2.37 on Wednesday, reflecting a positive market reaction to the financing and the company's outlook.
See More
